Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPX056 versus baclofen and placebo in multiple sclerosis-related spasticity
2007-000236-16Phase 3Completed
- Sponsor
- Impax Laboratories
- Start
- Mar 2007
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of IPX056 in multiple sclerosis (MS) and Muscle spasm (3 arms), sponsored by Impax Laboratories. Primary endpoint: Ashworth score. Started Mar 2007; status: completed.
02
Drugs
IPX056
03
Conditions
multiple sclerosis (MS)Muscle spasm
Beyond the preview
Go deeper on 2007-000236-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000236-16.